---
title: "Jincheng Pharm's subsidiary has obtained the European Pharmacopoeia suitability certificate for Oseltamivir phosphate chemical raw materials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250402553.md"
description: "According to the Zhitong Finance APP, Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. (referred to as \"Jincheng Tail\") recently received the European Pharmacopoeia suitability certificate for Oseltamivir Phosphate chemical raw materials issued by the European Directorate for the Quality of Medicines (EDQM). Oseltamivir Phosphate is a selective neuraminidase inhibitor for influenza viruses that can inhibit the further spread of the virus in the body, developed by Roche"
datetime: "2025-07-28T11:34:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250402553.md)
  - [en](https://longbridge.com/en/news/250402553.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250402553.md)
generator: "portal-rs"
---

# Jincheng Pharm's subsidiary has obtained the European Pharmacopoeia suitability certificate for Oseltamivir phosphate chemical raw materials

According to the Zhitong Finance APP, Jincheng Pharm (300233.SZ) announced that its wholly-owned subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. (referred to as "Jincheng Tail") recently received the European Pharmacopoeia suitability certificate for Oseltamivir Phosphate chemical raw materials issued by the European Directorate for the Quality of Medicines (EDQM). Oseltamivir Phosphate is a selective neuraminidase inhibitor for influenza viruses that can inhibit the further spread of the virus in the body, developed by Roche

### Related Stocks

- [300233.CN](https://longbridge.com/en/quote/300233.CN.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [Inbursa calls ordinary shareholders meeting](https://longbridge.com/en/news/298349345.md)
- [REG - CQS New City HighYld - Issue of Equity](https://longbridge.com/en/news/298224440.md)
- [GU Ventures portfolio firm PExA signs SEK 7.5 million deal with top-10 drugmaker](https://longbridge.com/en/news/298317808.md)
- [NFL Biosciences flags CESTO2 post-hoc analysis on NFL-101 smoking-cessation biomarker at SFT congress](https://longbridge.com/en/news/298271560.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**